Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-027295

Chief Financial Officer sold 2,500 shares at $15.47 ($38,675)

From the SEC's structured data for this filing

Trades in this filing

RAY DEBANJAN · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2017-07-03 Sale : show line 1 in the form −2,500 $15.47 $38,675 22,126 D
Open-market sales · 2,500 sh · avg $15.47 · $38,675
Loading xslF345X03/doc1.xml…